{
  "id": "3e3b300cf9bc",
  "type": "finding",
  "topic": "Zepbound Q4 2025 revenue forecast",
  "summary": "Zepbound Q3 2025 was $3,588.1M. Q4 2025 likely $3,800-4,200M based on growth trajectory, Q4 seasonality, and full-year guidance math.",
  "content": "Zepbound quarterly revenue: Q1'24 $517M, Q2'24 $1,243M, Q3'24 $1,258M, Q4'24 $1,907M, Q1'25 $2,312M, Q2'25 $3,381M, Q3'25 $3,588M. YTD 2025 $9,281M. Full-year Lilly guidance $63-63.5B, Q1-Q3 total $45.89B, implied Q4 total $17.1-17.6B. No negative pre-announcement for Q4 2025 (unlike Q4 2024). Japan launch April 2025 adds small international component. CVS formulary disruption resolved. Q4 seasonality typically positive.",
  "sources": [
    "https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd",
    "https://www.statista.com/statistics/1636037/eli-lilly-zepbound-revenue/"
  ],
  "confidence": 0.75,
  "question_id": 0,
  "report_path": "",
  "created_at": "2026-02-06T21:15:28.455089Z"
}